Home > Insider Trading > Filing (0001354488-14-001399)

Filing Details

Accession Number:: 0001354488-14-001399
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-03-25 17:16:31
Reporting Period:: 2014-03-03

Filing Date:: 2014-03-25
Accepted Time:: 2014-03-25 17:16:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1024126	Pernix Therapeutics Holdings Inc.	PTX	Pharmaceutical Preparations (2834)	330724736

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1486430	Jr. Edward James Smith	700 Camp St. New Orleans LA 70130		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-03-03	15,000	$3.59	4,987,704	No	4	S	Direct
Common Stock	Disposition	2014-03-04	15,000	$3.57	4,972,704	No	4	S	Direct
Common Stock	Disposition	2014-03-05	15,000	$3.57	4,957,704	No	4	S	Direct
Common Stock	Disposition	2014-03-06	15,000	$3.70	4,942,704	No	4	S	Direct
Common Stock	Disposition	2014-03-07	15,000	$3.68	4,927,704	No	4	S	Direct
Common Stock	Disposition	2014-03-10	15,000	$3.70	4,912,704	No	4	S	Direct
Common Stock	Disposition	2014-03-11	15,000	$3.78	4,897,704	No	4	S	Direct
Common Stock	Disposition	2014-03-12	15,000	$3.66	4,882,704	No	4	S	Direct
Common Stock	Disposition	2014-03-13	15,000	$3.68	4,867,704	No	4	S	Direct
Common Stock	Disposition	2014-03-14	15,000	$3.63	4,852,704	No	4	S	Direct
Common Stock	Disposition	2014-03-17	15,000	$3.62	4,837,704	No	4	S	Direct
Common Stock	Disposition	2014-03-18	15,000	$4.32	4,822,704	No	4	S	Direct
Common Stock	Disposition	2014-03-19	15,000	$4.75	4,807,704	No	4	S	Direct
Common Stock	Disposition	2014-03-20	15,000	$5.31	4,792,704	No	4	S	Direct
Common Stock	Disposition	2014-03-21	15,000	$5.51	4,777,704	No	4	S	Direct
Common Stock	Disposition	2014-03-24	15,000	$5.71	4,762,704	No	4	S	Direct
Common Stock	Disposition	2014-03-25	15,000	$5.73	4,747,704	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,200	Indirect	By daughter

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/3/14.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.46 to $3.74, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $_____ to $_____, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.49 to $3.68, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.54 to $3.81, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.73, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.78, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.92, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.74, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.76, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.66, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.54 to $3.75, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.60, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.44 to $4.94, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 to $5.52, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.96, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.95, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.62 to $5.85, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.